<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980538</url>
  </required_header>
  <id_info>
    <org_study_id>CR016408</org_study_id>
    <secondary_id>TMC125-TID35-C239</secondary_id>
    <secondary_id>2009-013126-16</secondary_id>
    <nct_id>NCT00980538</nct_id>
  </id_info>
  <brief_title>TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants</brief_title>
  <official_title>Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Sciences Ireland UC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Sciences Ireland UC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide etravirine (ETR) through this trial until
      participants can be switched to locally available ETR-based treatment regimens (that is,
      commercially available and reimbursed, or accessible through another source [example, access
      program or government program]), or local standard of care, as appropriate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is open label continued access trial for HIV-1 infected children/adolescents who have
      completed treatment in clinical (parent) trial with etravirine (ETR) sponsored by/in
      collaboration with Janssen Research &amp; Development and who continue to benefit from use of
      ETR. At baseline visit, eligibility criteria will be checked. If eligibility criteria are
      met, participants will either continue on ETR dose they received in previous ETR (parent)
      trial or on adjusted dose if required by investigator.ETR dose adjustment will be based on
      weight using dosing guidelines. Assessment visits are recommended every 3 months (pediatric)
      and 6 months (adults). For most of participant, their next visit will be final visit with
      data collection. New participants entering study, will have baseline visit without data
      collection. Thereafter visits and assessments will be performed per local standard of care
      and documented in the participant's medical records only. Investigators will continue to
      report SAEs possibly related to ETR and pregnancies to sponsor using regular reporting.
      Treatment will be continued until: investigator determines that participant no longer
      benefits from ETR treatment (e.g based on viral load); treatment limiting toxicity; loss to
      follow-up; consent withdrawal; pregnancy; program termination by Sponsor; ETR-based treatment
      regimen becomes commercially available for participant's use, and is reimbursed, or accessed
      by another source (e.g access/government program) in region participant is living, or
      participants switched to local standard of care, as appropriate. Adult participants will
      receive ETR 200mg BID.Pediatric participants will receive ETR, doses as received in previous
      ETR(parent) trial, with weight based dose adjustment if necessary.

      10 to &lt;20kg:100mg BID (4*25mg or 1 tablet 100mg) 20 to &lt;25kg:125mg BID (5*25mg or 1 tablet
      100mg+1 tablet 25mg) 25 to &lt;30kg:150mg BID (6*25mg or 1 tablet 100mg+2 tablets 25mg) &gt;=
      30kg:200mg BID (8*25mg or 2*100mg)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2009</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety until ETR-Based Treatment Regimen is Commercially Available</measure>
    <time_frame>Up to 14 years</time_frame>
    <description>An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. Treatment will continue until one of the following criteria is met: participant no longer benefits from ETR treatment, toxicity, loss to follow up, etravirine becomes commercially available for participants' use.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>HIV Infections</condition>
  <condition>HIV-1</condition>
  <arm_group>
    <arm_group_label>Etravirine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etravirine Dosed by weight up to a maximum dose of 200 milligram (mg) bid until switched to an etravirine (ETR)-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etravirine</intervention_name>
    <description>Participants will be dosed with etravirine by weight up to a maximum dose of 200 mg bid until switched to an etravirine-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.</description>
    <arm_group_label>Etravirine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants who meet all of the following criteria are eligible for this trial:
             Documented HIV-1 infection

          -  Male or female participants, aged 2 years and older

          -  Successfully completed a clinical (parent) pediatric trial with ETR sponsored by or in
             collaboration with Janssen Research &amp; Development, and continues to receive benefit
             from the use of ETR

          -  Participant (where appropriate, depending on age) and their parent(s) or legal
             representative(s) have signed the Informed Consent Form (ICF)/Assent voluntarily

          -  Children will be informed about the program and asked to give assent (where
             appropriate, depending on age)

          -  Negative urine pregnancy test for females of childbearing potential

        Exclusion Criteria:

          -  Participants meeting one or more of the following criteria cannot be selected: Any
             condition (including but not limited to alcohol and drug use), which in the opinion of
             the investigator could compromise the participant's safety or adherence to treatment
             with ETR

          -  Any active clinically significant disease (e.g., pancreatitis, cardiac dysfunction) or
             findings of medical history, laboratory or physical examination that, in the
             investigator's opinion, would compromise the participant's safety during treatment
             with ETR

          -  Previously demonstrated clinically significant allergy or hypersensitivity to ETR or
             to any of the excipients of ETR

          -  Pregnant or breastfeeding

          -  Non-vasectomized heterosexually active boys not using safe and effective birth control
             methods, or not willing to continue practicing these birth control methods, during the
             trial and until 30 days after the end of the trial (or after the last intake of the
             investigational medication)

          -  Girls, who are sexually active and able to become pregnant, not using safe and
             effective birth control methods, or not willing to continue practicing these birth
             control methods, during the trial and until 30 days after the end of the trial (or
             after the last intake of the investigational medication)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Sciences Ireland UC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Sciences Ireland UC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:</last_name>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Childrens Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Howard University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson Medical School Pediatric Clinical Research Center</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>St Christopher'S Hospital For Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>St Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Children'S Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Helios Salud Sa</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1141ACG</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Pediatria 'J.P. Garrahan'</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1245AAM</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Fundacion Huesped</name>
      <address>
        <city>Ciudad Autonoma De Buenos Aire</city>
        <zip>C1202ABB</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Señora de la Misericordia</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>SOM Federal University Minas Gerais Brazil</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30.130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas da Universidade Federal De Minas Geraisnas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Das Clínicas Da Faculdade de Medicina de Ribeirão Preto</name>
      <address>
        <city>Riberao Preto</city>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Dos Servidores Do Estado</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20221-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital federal dos servidores do estado</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20221</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21941</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Geral de Nova Iguacu - HGNI DST/AIDS</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>26030-380</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Montreal Children's Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hop. Ste-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Institut D'Hematologie Et D'Oncologie Pediatrique</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Meyer - Unita Operativa Di Malattie Infettive Pediatriche</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedale Universita San Martino Di Genoa - U.O. Malattie Infettive</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinica Pediatrica De Marchi</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Luigi Sacco</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Universtà Degli Studi Di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ospedale del Bambino Gesu</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Pan-American Medical Research Institute, S.A.</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Punta Pacífica</name>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Spitalul de Boli Infectioase si Tropicale 'Dr. Victor Babes'</name>
      <address>
        <city>Bucuresti</city>
        <zip>030317</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Boli Infectioase Constanta</name>
      <address>
        <city>Constanta</city>
        <zip>900178</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Farmouvs Parexel</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9300</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Josha Research</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wilhase A.C. Private Practice</name>
      <address>
        <city>Boksburg</city>
        <zip>1459</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu Hiv Foundation - University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Jan Fourie Medical Practice</name>
      <address>
        <city>Dundee</city>
        <zip>3000</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synapta Clinical Research</name>
      <address>
        <city>Durban N/a</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>203 Maxwell Centre</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Excellentis Clinical trial Consultants</name>
      <address>
        <city>George</city>
        <zip>6529</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>WWCT</name>
      <address>
        <city>Johannesburg</city>
        <zip>1501</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Soweto Clinical Trial Centre</name>
      <address>
        <city>Johannesburg</city>
        <zip>1818</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shandukani Research Centre</name>
      <address>
        <city>Johannesburg</city>
        <zip>2001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Innovir Institute</name>
      <address>
        <city>Johannesburg</city>
        <zip>2007</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Witwatersrand - Helen Joseph Hospital - Themba Lethu Hiv Research Centre</name>
      <address>
        <city>Johannesburg</city>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Newtown Clinical Research</name>
      <address>
        <city>Newtown</city>
        <zip>2113</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trialtech Clinical Research Institute</name>
      <address>
        <city>Pretoria N/a</city>
        <zip>0083</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gct Sunnyside</name>
      <address>
        <city>Pretoria</city>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>H. San Joan de Deu</name>
      <address>
        <city>Esplugues De Llobregat</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital de 12 Octobre, Unidad Vih</name>
      <address>
        <city>Madrid N/a</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Madrid</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Thai Red Cross Aids Research Centre</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Siriraj hospital - Faculty of Medicine,Mahidol University - Department of Pediatrics</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Panama</country>
    <country>Romania</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Guatemala</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR016408</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2009</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TMC125-TiDP35-C239</keyword>
  <keyword>TMC125-C239</keyword>
  <keyword>TMC125</keyword>
  <keyword>HIV</keyword>
  <keyword>Etravirine</keyword>
  <keyword>Intelence</keyword>
  <keyword>IntelenceTM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etravirine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

